Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Study Identifier
P25-187
CT.gov Identifier
NCT07039110
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Recruiting
Sign up for trial alerts

Study Details

Medical Condition
  • Dermatology - Psoriasis (PsO)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment. * Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines. * Decision to treat with risankizumab is made prior to and independently of study participation.
    Exclusion Criteria:
    * History of a sleep disorder diagnosis which the patient is currently being treated for. * Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study. * Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.

    Protocol Summary

    Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice.

    Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide.

    Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years.

    There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

    Study Locations

    Location
    Status
    Location
    Rejuvenation Dermatology - Edmonton Downtown /ID# 276688
    Edmonton, Alberta, Canada, T5J 3S9
    Status
    Recruiting
    Location
    Winnipeg Clinic /ID# 276751
    Winnipeg, Manitoba, Canada, R3C 1T6
    Status
    Recruiting
    Location
    Wiseman Dermatology Research /ID# 276847
    Winnipeg, Manitoba, Canada, R3M 3Z4
    Status
    Recruiting
    Location
    Cca Medical Research /ID# 276944
    Ajax, Ontario, Canada, L1S 7K8
    Status
    Recruiting
    Location
    Quinte dermatology /ID# 277497
    Belleville, Ontario, Canada, K8N 2S9
    Status
    Recruiting
    Location
    Dermatrials Research /ID# 276714
    Hamilton, Ontario, Canada, L8N 1Y2
    Status
    Completed
    Showing {first} - {last} of {total} Results